A San Francisco Bay Area biotech firm was cleared of any wrongdoing last week when a federal jury in Philadelphia rejected the claims of an ophthalmologist who alleged he was cheated out of his promised share of the profits from a new treatment for macular degeneration — the leading cause of blindness in people over the age of 60.

In the suit, plaintiff Kourosh A. Dastgheib claimed that he had provided “vitally important” research to Genentech Inc. that led to its development of the drug Lucentis, but that the company reneged on its promise to give him 1 percent of its gross revenues and professional recognition for his role in discovering the drug.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]